Technology & Innovation

South: HMT advises Maven on genetic testing investment

Published by
TBM Team

HMT LLP, led by partner Paul Read and manager Andrew Reid, advised Maven Capital Partners on its investment in Gen inCode, a genetic testing business specialising in the risk assessment and prediction of cardiovascular disease.

Founded in 2018, Gen inCode has developed a range of patented DNA risk assessment products which utilise AI, bioinformatics and a globally recognised clinical evidence base to provide predictive analysis of a patient’s health risk.

Proprietary algorithms are used to predict the probability of adverse events, resulting in a comprehensive risk evaluation that provides key insights into a patient’s susceptibility to disease and clinically actionable results that empower patients to take steps to reduce their risk. 

Gen inCode’s advanced clinical diagnostic tests cover major global disease areas such as Cardiovascular, Cancer and Diabetes. Its solutions are enabling healthcare practitioners to identify high risk patients and proactively develop targeted treatment and prevention plans; helping to transform the delivery of healthcare, reduce costs and improve patient outcomes. 

Gen inCode raised in total £3.4 million from this funding round, with the Maven VCTs co-investing £1.5m alongside Downing LLP and existing private shareholders. The business has built up a strong IP portfolio and today’s funding will enable the business to expand overseas, particularly in the US, capitalising on the growth in emerging precision medicine market. 

HMT undertook financial due diligence for Maven on this transaction. 

Dale Bellis, investment director at Maven, commented: “The HMT Team did a great job in supporting Maven on our recent investment into Gen inCode. The team provided invaluable and comprehensive advice throughout the process and we forward to working with HMT again on future transactions.” 

Paul Read commented: “We are delighted to have advised Maven on yet another transaction this year. The precision medicine sector is currently booming and innovative healthcare businesses such as Gen inCode are well positioned to grow and develop. We look forward to working with them again in the future.”

TBM Team

Recent Posts

Halma acquires safety tech firm MK Test in £44m deal

Buckinghamshire tech company Halma has acquired transport safety firm MK Test Systems Limited. Headquartered in…

9 hours ago

Paragon Bank provides finance for West Sussex housing development

BRiCS Development has secured an £11.55 million finance facility with Paragon Bank’s Development Finance team…

10 hours ago

IT firm Mintivo appoints new Managing Director

IT services and solutions company Mintivo has appointed Alex Jukes as its new Managing Director…

10 hours ago

Bartlett Tree Experts to build new research facility in Wokingham woodland

Bartlett Tree Experts have announced its intention to build a new arboretum and research facility…

10 hours ago

New £3m imaging system to be developed at University of Surrey

The creation of a first-of-its-kind imaging system at the University of Surrey could help the…

10 hours ago

New chair of trustees at Open Sight Hampshire

Open Sight, which provides support across Hampshire to those living with or at risk of…

12 hours ago